Introduction
============

Despite standard platinum-based chemotherapy and newer targeted therapies, patients with advanced non-small cell lung cancer (NSCLC) inevitably experience disease progression. In addition to the use of maintenance and second-line therapies as standard-of-care, there is an increasing need for the appropriate use of targeted and tailored therapies to improve efficacy and tolerability in patients with advanced NSCLC.

Pemetrexed (Alimta, Eli Lilly and Company), a multitargeted antifolate, is a standard-of-care for first-line \[[@b1-crt-2014-051]\], maintenance \[[@b2-crt-2014-051]\], and second-line \[[@b3-crt-2014-051]\] treatment of nonsquamous advanced NSCLC. Furthermore, a subgroup analysis of a phase III global study showed that pemetrexed plus platinum therapy improved overall survival (OS) compared with gemcitabine plus platinum therapy in a subgroup of East Asian (EA) patients with advanced nonsquamous NSCLC \[[@b4-crt-2014-051]\]. Results from Asian studies have also demonstrated the efficacy of pemetrexed in the second-line setting \[[@b5-crt-2014-051],[@b6-crt-2014-051]\].

Erlotinib (Tarceva, OSI-774, OSI Pharmaceuticals/Genentech), a reversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) as monotherapy has previously demonstrated significantly improved survival versus placebo in patients with advanced NSCLC as a second- or third-line therapy \[[@b7-crt-2014-051],[@b8-crt-2014-051]\]. Activating mutations in the *EGFR* gene are associated with a high sensitivity to EGFR TKIs and the treatment of patients with NSCLC carrying *EGFR* mutations with EGFR TKIs results in prolongation of progression-free survival (PFS) and higher response rates compared with standard chemotherapy \[[@b9-crt-2014-051]\]. In addition, it has been reported that *EGFR* mutations are present predominantly in women never-smokers, individuals with adenocarcinoma and those of EA ethnicity \[[@b10-crt-2014-051]-[@b12-crt-2014-051]\].

Previous attempts to combine chemotherapy and EGFR TKIs have produced mixed results in unselected populations \[[@b13-crt-2014-051]-[@b16-crt-2014-051]\]. Currently, there is no consensus on the use and additive effect of chemotherapy and TKIs in the treatment of advanced NSCLC. In an attempt to improve the outcomes of the combination therapy, Lee et al. \[[@b17-crt-2014-051]\] conducted a study comparing erlotinib plus pemetrexed versus each single agent in a clinically enriched population of never-smoker patients with advanced nonsquamous NSCLC. In this study, pemetrexed-erlotinib combination therapy significantly improved PFS compared with either drug alone in this selected population. Upon subsequent testing, the incidence of *EGFR* mutations in this clinically selected population who provided evaluable samples was 55.8%.

In an exploratory analysis of patients with *EGFR* mutations, the combination therapy showed a PFS advantage over pemetrexed but not over erlotinib; OS was numerically improved for the combination over both single agents \[[@b17-crt-2014-051]\]. Due to the distinctive characteristics of EGFR-expressing NSCLC in Asian patients compared with Caucasian patients, this exploratory analysis assessed the possible association of ethnicity (EA and non-EA populations) with efficacy and safety in the phase II global trial \[[@b17-crt-2014-051]\].

Materials and Methods
=====================

1. Study design and treatment plan
----------------------------------

Details regarding the study design and treatment were described previously \[[@b17-crt-2014-051]\]. This was an exploratory analysis of the multicenter, open-label, randomized, phase II global trial conducted in never-smokers with advanced nonsquamous NSCLC by Lee et al. \[[@b17-crt-2014-051]\]. In this trial, 247 patients who had histological or cytological diagnosis of locally advanced or metastatic NSCLC, had failed only one prior chemotherapy regimen, and were eligible for further chemotherapy following disease progression were randomly assigned in a ratio of 1:1:1 to pemetrexed plus erlotinib, erlotinib alone, or pemetrexed alone. Patients with squamous histology (n=7) were excluded from the primary analysis. In the exploratory analysis reported here, only those patients enrolled in China, Hong Kong, Korea, and Taiwan were considered for inclusion in the EA population (n=133, 55.4%) and patients enrolled in Australia, Brazil, India, and the United Kingdom were considered for inclusion in the non-EA population (n=107, 44.6%)

Pemetrexed (500 mg/m^2^) was administered intravenously on day 1 of a 3-week cycle. Erlotinib (150 mg, orally) as a single agent was administered once daily continuously and, when taken in combination with pemetrexed, once daily from day 2 through day 14 of a 3-week cycle. All patients treated with pemetrexed received dexamethasone, folic acid, and vitamin B~12~. Patients continued to receive study therapy until disease progression, or any other discontinuation criterion was met.

The global trial \[[@b17-crt-2014-051]\] was conducted according to the Declaration of Helsinki and good clinical practice guidelines and was approved by each participating institution and its ethical review board. All patients signed a written informed consent form before treatment. The ClinicalTrials.gov Identifier is NCT00550173.

2. Baseline and treatment assessments
-------------------------------------

Details of the treatment assessments have been previously reported \[[@b17-crt-2014-051]\]. Tumors were measured by the same imaging method(s) within 4 weeks before randomization, every 6 weeks (±1 week) during therapy, and every 6 weeks (±1 week) post--study-drug therapy, until disease progression, death, or 18 months after randomization for patients with objective response (complete response or partial response) or stable disease at the time of discontinuation of study therapy. Details of the biomarker analysis have been previously reported \[[@b17-crt-2014-051]\].

3. Statistical analyses
-----------------------

The primary efficacy endpoint in the global trial was PFS and secondary endpoints included OS, objective response rate (ORR), and safety assessment \[[@b17-crt-2014-051]\]. In this report, PFS, OS, ORR, and toxicities between treatment arms in the EA and non-EA populations were reported. The analyses in the EA and non-EA populations used the same methodology as that used in the primary analysis of the qualified intention-to-treat (ITT) population \[[@b17-crt-2014-051]\]. The reverse Kaplan-Meier estimator methodology \[[@b18-crt-2014-051]\] was used to calculate the median follow-up time.

Post-hoc exploratory subgroup analyses for PFS and OS were conducted on selected subgroups of EA and non-EA patients using the same multivariate Cox regression models adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS; 0-1 vs. 2), sex (male vs. female), and age (≤ 65 years vs. \> 65 years). All tests were conducted at a two-sided 0.05 significance level unless otherwise stated and p-values were not adjusted for multiplicity. The incidence of *EGFR* mutations was calculated as the number of *EGFR* mutations over the number of *EGFR* evaluable samples. Due to the small sample size of the EGFR subgroups (mutationpositive and mutation-negative) in each treatment arm, comparative analyses between arms were not appropriate. Instead, descriptive analyses of PFS and OS were conducted on EGFR subgroups.

Safety endpoints were analyzed on nonsquamous patients who received at least one dose of study therapy and according to the treatment they received in the first cycle. Safety analyses included summaries of the incidence of adverse events (AEs) by maximum Common Terminology Criteria for Adverse Events (CTCAE) ver. 3.0 grade.

Results
=======

1. Patients and treatment
-------------------------

The 240 patients comprised 133 EA patients randomized to erlotinib-pemetrexed (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to erlotinib-pemetrexed (n=37), erlotinib (n=33), or pemetrexed (n=37). The proportion of female patients was comparatively higher than the proportion of male patients in the EA and non-EA populations ([Table 1](#t1-crt-2014-051){ref-type="table"}). The proportion of patients with PS 1 was higher than the proportion of patients with PS 0 in the EA and non-EA populations. A higher proportion of patients in the EA population were from the Republic of Korea (39.8%, 53/133). Similarly, a higher proportion of patients in the non-EA population were from India (62.6%, 67/107). The EGFR mutation status was unknown in the majority of patients in both of these populations (EA, 102/133 \[76.7%\] and non-EA, 95/107 \[88.8%\]). Within the limits of a relatively small number of samples tested, the proportion of patients with *EGFR* mutation was comparatively higher in the EA population with known test results (61.3%, 19/31) compared with those in the non-EA population (41.7%, 5/12). Notably, the EGFR mutation status was not known at baseline and therefore, it was not used as a stratification factor.

2. Efficacy
-----------

### 1) Primary efficacy measure

The analysis of the primary endpoint, PFS, was conducted for the EA and non-EA populations ([Fig. 1A](#f1-crt-2014-051){ref-type="fig"} and [C](#f1-crt-2014-051){ref-type="fig"}). In the EA population, a statistically significant difference in PFS was observed among the three arms (overall p=0.003), with the pemetrexed-erlotinib combination significantly improving PFS as compared with either single-agent arm (pemetrexed-erlotinib vs. erlotinib, p=0.004; pemetrexed-erlotinib vs. pemetrexed, p=0.001) ([Table 2](#t2-crt-2014-051){ref-type="table"}). No statistically significant difference was noted between pemetrexed and erlotinib (p=0.430) ([Table 2](#t2-crt-2014-051){ref-type="table"}). The EA patients treated with the pemetrexed-erlotinib combination had a longer median PFS (7.4 months; 95% CI, 5.3 to 15.3 months) compared with those treated with erlotinib (4.5 months; 95% CI, 2.7 to 11.1 months; p=0.016) and pemetrexed (4.0 months; 95% CI, 2.9 to 6.7 months; p=0.006).

In the non-EA population, the PFS results also numerically favored the pemetrexed-erlotinib combination; however, the PFS differences were not statistically significant (overall p=0.210) for the pemetrexed-erlotinib combination compared with either agent alone (pemetrexed-erlotinib vs. erlotinib, p=0.078; pemetrexed-erlotinib vs. pemetrexed, p=0.320) ([Table 2](#t2-crt-2014-051){ref-type="table"}). Similarly, no statistically significant difference was noted between pemetrexed and erlotinib (p=0.505) ([Table 2](#t2-crt-2014-051){ref-type="table"}). The median PFS in the pemetrexed-erlotinib arm was 6.7 months (95% CI, 1.8 to 13.2 months) compared with 3.0 months for erlotinib (95% CI, 1.8 to 5.6 months; p=0.061) and 4.4 months for pemetrexed (95% CI, 2.1 to 7.2 months; p=0.512).

### 2) Secondary efficacy measures

In the EA population, numerically improved OS was noted among the three treatment arms ([Fig. 1B](#f1-crt-2014-051){ref-type="fig"}), but the OS did not reach statistical significance (overall p=0.114; pemetrexed-erlotinib vs. erlotinib: hazard ratio \[HR\], 0.83; and pemetrexed-erlotinib vs. pemetrexed: HR, 0.53) ([Table 2](#t2-crt-2014-051){ref-type="table"}).

Similarly, in the non-EA population, the HR for PFS favored the combination (pemetrexed-erlotinib vs. erlotinib: HR, 0.62; pemetrexed-erlotinib vs. pemetrexed: HR, 0.75); however, in contrast to the HRs for OS in the EA population, the HRs for OS in the non-EA population did not show any clear advantage in favor of the combination (pemetrexed-erlotinib vs. erlotinib: HR, 1.42; pemetrexed-erlotinib vs. pemetrexed: HR, 1.00) ([Table 2](#t2-crt-2014-051){ref-type="table"}).

A long OS was noted in this second-line NSCLC population, independent of treatment arm \[[@b17-crt-2014-051]\]. This was particularly evident in the EA population, in which the median OS was 25.0 months (95% CI, 20.1 to 37.5 months) for pemetrexed-erlotinib, 25.3 months (95% CI, 18.2 to not applicable) for erlotinib, and 19.5 months (95% CI, 11.8 to 26.9 months) for pemetrexed. Also in the non-EA population, longer than expected OS occurred ([Fig. 1D](#f1-crt-2014-051){ref-type="fig"}), although the medians for OS in the non-EA population were shorter than those in the EA patients. The median OS was 19.2 months (95% CI, 4.5 to 20.5 months) for pemetrexed-erlotinib, 20.6 months (95% CI, 6.8 to 25.3 months) for erlotinib, and 12.7 months (95% CI, 6.9 to 23.1 months) for pemetrexed. In the non-EA population, no statistically significant difference in OS was observed among the three treatment arms (overall p=0.528) ([Table 2](#t2-crt-2014-051){ref-type="table"}, [Fig. 1](#f1-crt-2014-051){ref-type="fig"}). The median length of follow-up from the date of enrollment was 22.4 months (95% CI, 20.1 to 25.6 months) in EA patients and 18.4 months (95% CI, 12.3 to 29.6 months) in non-EA patients.

Consistent with the results of improved PFS for the pemetrexed-erlotinib combination, a statistically significant difference in ORR was observed among the three arms in the EA population (p \< 0.001) ([Table 3](#t3-crt-2014-051){ref-type="table"}). The ORR was 51.2% for pemetrexed-erlotinib, 30.6% for erlotinib, and 11.6% for pemetrexed. Overall, a statistically significant difference in ORR was observed across the three arms (overall p \< 0.001), with the pemetrexed-erlotinib combination resulting in significantly higher ORR compared with either single-agent arm (pemetrexed-erlotinib vs. erlotinib, p=0.027; pemetrexed-erlotinib vs. pemetrexed, p \< 0.001) ([Table 3](#t3-crt-2014-051){ref-type="table"}). There was a numerical, but not statistically significant, difference in the disease control rate (DCR) among the three treatment arms (p=0.107). For pemetrexed-erlotinib, the DCR was 70.7% ([Table 3](#t3-crt-2014-051){ref-type="table"}). Pemetrexed-erlotinib had a significantly higher DCR than erlotinib alone (p=0.033) or pemetrexed alone (p=0.048) ([Table 3](#t3-crt-2014-051){ref-type="table"}).

In the non-EA population, a statistically significant difference in ORR was noted among the three treatment arms (p=0.013) ([Table 3](#t3-crt-2014-051){ref-type="table"}). The ORR was 37.1% for pemetrexed-erlotinib, 27.3% for erlotinib, and 8.1% for pemetrexed. Pemetrexed-erlotinib had a significantly higher ORR than pemetrexed (p=0.010). The ORR for pemetrexed-erlotinib was not significantly higher than that for erlotinib (p=0.389) ([Table 3](#t3-crt-2014-051){ref-type="table"}). No statistically significant difference in the DCR was noted among the three treatment arms (p=0.804). The DCR was 57.1% for pemetrexed-erlotinib, 54.5% for erlotinib, and 62.2% for pemetrexed ([Table 3](#t3-crt-2014-051){ref-type="table"}).

3. Exploratory analyses
-----------------------

Exploratory subgroup analyses for the EA and non-EA populations are presented in [Fig. 2A](#f2-crt-2014-051){ref-type="fig"} and [B](#f2-crt-2014-051){ref-type="fig"}. Subgroup analyses of PFS in the EA population showed that the benefit of the combination was consistent across most clinical subsets including sex, ECOG PS, and age ([Fig. 2A](#f2-crt-2014-051){ref-type="fig"} and [B](#f2-crt-2014-051){ref-type="fig"}). In the non-EA population, the pemetrexed-erlotinib combination resulted in numerically higher PFS over pemetrexed alone or erlotinib alone for most subgroups ([Fig. 2E](#f2-crt-2014-051){ref-type="fig"} and [F](#f2-crt-2014-051){ref-type="fig"}). No statistically significant difference for OS was observed among treatment arms ([Fig. 2C](#f2-crt-2014-051){ref-type="fig"}, [D](#f2-crt-2014-051){ref-type="fig"}, [G](#f2-crt-2014-051){ref-type="fig"}, and [H](#f2-crt-2014-051){ref-type="fig"}). PFS and OS results for the ECOG PS 2 subset were not reported for the EA and non-EA populations due to the small sample sizes.

In the EA population, the *EGFR* mutation status (positive or negative) was available for 31 patients and the incidence of *EGFR* mutation was 61.2% (19/31 patients). In the non-EA population, *EGFR* mutation status was available for 12 patients, and the incidence of *EGFR* mutation was 41.7% (5/12) ([Table 1](#t1-crt-2014-051){ref-type="table"}).

Descriptive comparisons of PFS and OS by *EGFR* mutation subsets for the EA and non-EA populations are presented in [Appendix 1](#app1-crt-2014-051){ref-type="app"}. In the overall and EA populations, *EGFR* mutation positive patients generally had longer PFS compared with *EGFR* negative patients, independent of treatment received ([Appendix 1A](#app1-crt-2014-051){ref-type="app"}-[D](#app1-crt-2014-051){ref-type="app"}). In the EA population, *EGFR* mutation-negative patients treated with erlotinib seemed to have shorter PFS compared with EA patients treated with pemetrexed alone or the pemetrexed-erlotinib combination ([Appendix 1E](#app1-crt-2014-051){ref-type="app"}). Among the three arms, the combination arm appeared to provide the best PFS benefit in *EGFR* mutation-negative patients in the EA population ([Appendix 1E](#app1-crt-2014-051){ref-type="app"}). OS was similar across treatment arms and *EGFR* mutation status subsets in the EA and non-EA populations, with few exceptions ([Appendix 1F](#app1-crt-2014-051){ref-type="app"} and [H](#app1-crt-2014-051){ref-type="app"}). The small sample size, however, limits the interpretation of the observed trends.

4. Post-discontinuation treatment
---------------------------------

Overall, in the EA population, 90 patients (67.7%) received at least one post-discontinuation treatment (PDT). In particular, 63 patients (47.4%) received systemic chemotherapy, 36 (27.1%) received EGFR TKIs, and 26 patients (19.5%) received radiation therapy. In comparison, fewer patients 29 (27.1%) in the non-EA population received at least one PDT (systemic chemotherapy in 19 patients \[17.8%\]; EGFR TKIs in 7 patients \[6.5%\]; and radiation therapy in 8 patients \[7.5%\]).

5. Safety
---------

The overall incidence of at least one high-grade (grade 3/4) study drug-related treatment-emergent adverse events (TEAEs) was low in both the EA (39 \[30.0%\]) and non-EA (38 \[36.5%\]) populations. The pemetrexed-erlotinib combination in the EA population generally had a higher incidence of drug-related grade 3 or 4 TEAEs than either single agent alone ([Table 4](#t4-crt-2014-051){ref-type="table"}). Similarly, in the non-EA population, patients in the pemetrexed-erlotinib combination arm generally had a higher incidence of drug-related grade 3 or 4 TEAEs than either single agent alone. Common drug-related grade 3 and 4 TEAEs in pemetrexed-erlotinib, erlotinib, and pemetrexed in the EA population included neutropenia (27.5%, 0%, and 15.0%), anemia (10.0%, 0%, and 7.5%), and lymphopenia (7.5%, 0%, and 10.0%). Common drug-related grade 3 and 4 TEAEs in pemetrexed-erlotinib, erlotinib, and pemetrexed in the non-EA population included neutropenia (20.0%, 0%, and 13.9%), leukopenia (17.1%, 0%, and 8.3%), and lymphopenia (17.1% 0%, and 2.8%) ([Table 4](#t4-crt-2014-051){ref-type="table"}). No drug-related deaths were reported in the EA population. Five non-EA patients (2 in the pemetrexed-erlotinib arm and 3 in the pemetrexed arm) died during the study from study drugrelated AEs ([Table 4](#t4-crt-2014-051){ref-type="table"}).

Discussion
==========

This is an exploratory subgroup analysis of the EA and non-EA populations in the recently reported phase II, randomized, controlled trial \[[@b17-crt-2014-051]\]. In this trial, the combination of pemetrexed-erlotinib was compared with either pemetrexed or erlotinib alone as second-line treatment in a selected population of never-smoking patients with locally advanced or metastatic nonsquamous NSCLC \[[@b17-crt-2014-051]\].

In this global trial \[[@b17-crt-2014-051]\], never-smoker patients were selected in an attempt to "enrich" the patient population for potential EGFR TKI sensitivity. At the inception of this study, data from the Iressa Pan-Asia Study (IPASS) \[[@b19-crt-2014-051]\] trial and the critical importance of *EGFR* mutational status were not available to determine sensitivity to EFGR TKIs. Therefore, molecular profiling of patients for *EGFR* mutations was only included as an exploratory analysis in this study. The results from the current subgroup analysis support other findings \[[@b20-crt-2014-051]\] that the pemetrexed-erlotinib combination enhances activity compared with single-agent treatment.

The PFS results in this exploratory subgroup analysis were consistent with the results of the PFS results in the overall qualified ITT population \[[@b17-crt-2014-051]\], particularly for the EA population, demonstrating that the pemetrexed-erlotinib combination significantly prolonged PFS and led to a longer median PFS compared with either agent alone. Similarly, the pemetrexed-erlotinib combination therapy had numerically superior PFS in the non-EA population; however, the difference in the non-EA population was not significant (p=0.210). Subgroup analyses of PFS in the EA population in this study also showed that the benefit of the combination was consistent across the clinical subsets including gender, ECOG PS, age, and EGFR-positive status. Note that the analysis was powered only for PFS in the overall ITT population, not any particular subgroup populations. It is expected that the statistical tests, when restricted to subgroup populations (e.g., non-EA), are underpowered. Thus, the results reported in this manuscript need to be interpreted in the context of this limitation.

Overall, numerically improved but not statistically significant OS was noted among the three treatment arms in the EA, non-EA, and ITT \[[@b17-crt-2014-051]\] populations. Of note, neither the global trial \[[@b17-crt-2014-051]\] nor this subgroup analysis was powered for OS. Similar to the ITT population \[[@b17-crt-2014-051]\], among the three treatment arms, the censoring rates were high in the EA and non-EA populations, which may also have limited the analysis for OS. In addition, the median OS in the EA population was notably long, ranging from 19.5 to 25.3 months among the three treatment arms and from 12.7 to 20.6 months in the non-EA population. The longer median OS in EA patients is consistent with longer median OS reported previously \[[@b21-crt-2014-051]\] and may be due to several factors, including the higher incidence of *EGFR* mutations and the more frequent use of PDT, including the addition of cross-over treatment with pemetrexed and EGFR TKIs. The pemetrexed-erlotinib combination also had a stronger effect on ORR and DCR in the EA population compared with that in the non-EA population.

Recently, increased evaluation of biomarkers has enhanced our understanding of the complex NSCLC biology and has aided in the development of targeted drugs and tailored strategies for the treatment of advanced NSCLC. In a prospective biomarker study in patients with NSCLC, *EGFR* mutation has been identified as the strongest predictive factor for outcomes with EGFR TKIs \[[@b22-crt-2014-051]\].

In our study, never-smoking status was used as a clinical enriching factor for sensitivity to EGFR TKIs, which led to a higher proportion of patients with *EGFR* mutations. As expected, the incidence of *EGFR* mutation in patients evaluated for a somatic mutation was higher in the EA and non-EA populations, at 61% and 42%, respectively, than in the average Caucasian \[[@b23-crt-2014-051]\] or Asian populations with NSCLC. In comparison, the IPASS \[[@b19-crt-2014-051]\] and First-SIGNAL \[[@b24-crt-2014-051]\] studies reported 60% and 44% of EA never-smokers or former light smokers with pulmonary adenocarcinoma were positive for *EGFR* mutations, respectively. As a limitation of this study, the EGFR mutation status was unknown for the majority of patients (EA population, 76.7%; vs. non-EA population, 88.8%).

In this study, pemetrexed-erlotinib improved PFS compared with single agents alone in the EA population. The pemetrexed-erlotinib combination therapy had numerically superior PFS in the non-EA population. Given the small number of patients, the descriptive analysis of *EGFR* mutation status (positive and negative) in the EA and non-EA populations cannot conclusively identify clear trends. The fact that the majority of patients on this study had unknown *EGFR* mutation status greatly limits the conclusions and underscores the importance of routine molecular profiling in advanced NSCLC.

Conclusion
==========

In conclusion, the subset analysis presented in this study and recent findings suggest that the combination of EGFR TKIs and pemetrexed may benefit selected populations of patients with nonsquamous NSCLC. This hypothesis needs to be tested in prospective randomized clinical trials of second- or first-line therapy in patients with EGFR profiling to expand our insight regarding the role of chemotherapy and EGFR TKI combinations.
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![Box and scatter plots of progression-free survival (PFS) and overall survival (OS) for epidermal growth factor receptor (*EGFR*) mutation positive and *EGFR* mutation-negative subsets. (A, B) Box plot of PFS and OS, respectively, for the entire population. (C, D) Box plot of PFS and OS, respectively, for East Asian (EA) population. (E, F) Scatter plot of PFS and OS, respectively, by treatment group in the EA population. (G, H) Scatter plot of PFS and OS, respectively, by treatment group in the non-EA population. Note: Patient with any *EGFR* mutation detected was categorized as mutated (positive); patient without *EGFR* mutations detected was categorized as non-mutated (negative); (A-D) the distribution of the middle half of the data was displayed by a box with the bottom, center, and top lines indicating quartile 1, median, and quartile 3, respectively. Potential outliers are plotted as individual points. The vertical lines extend from the bottom and top of the box to the smallest or largest non-outliers. (G, H) There were no non-EA erlotinib-treated *EGFR* mutation positive patients or non-EA pemetrexed-treated *EGFR* mutation-negative patients. Erl, erlotinib; Pem, pemetrexed.](crt-2014-051a1){#a1-crt-2014-051a1}

![Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) for East Asian (EA) and non-EA populations. (A) Kaplan-Meier plot of PFS for EA population. (B) Kaplan-Meier plot of OS for EA population. (C) Kaplan-Meier plot of PFS for non-EA population. (D) Kaplan-Meier plot of OS for non-EA population. For OS, 53.7%, 37.2% and 53.1% of EA patients and 35.1%, 40.5% and 54.5% of non-EA patients treated with pemetrexed-erlotinib, pemetrexed or erlotinib, respectively, were censored.](crt-2014-051f1){#f1-crt-2014-051}

![Forest plots by clinical subgroups (qualified intention-to-treat population). (A, B) Forest plots of progression-free survival (PFS) for East Asian (EA) population by clinical subgroups. (C, D) Forest plots of overall survival (OS) for EA population by clinical subgroups. (E, F) Forest plots of PFS for non-EA population by clinical subgroups. (G, H) Forest plots of OS for non-EA population by clinical subgroups. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio. ^a)^Patient with any *EGFR* mutation detected was categorized as mutated (positive); patient without *EGFR* mutations detected was categorized as non-mutated (negative); patient without *EGFR* samples or without valid *EGFR* samples was categorized as unknown. Note: The results for Eastern Cooperative Oncology Group performance status (ECOG PS) 2 subgroup were removed from the plot due to the extremely small number of patients in the EA (n=6) and non-EA (n=10) populations.](crt-2014-051f2){#f2-crt-2014-051}

###### 

Baseline demographic and disease characteristics (East Asian and non-East Asian ITT population)

  Parameter                                                                  East Asian   Non-East Asian                                          
  -------------------------------------------------------------------------- ------------ ---------------- ------------ ------------ ------------ ------------
  Gender                                                                                                                                          
   Male                                                                      8 (19.5)     14 (28.6)        15 (34.9)    12 (32.4)    14 (42.4)    20 (54.1)
   Female                                                                    33 (80.5)    35 (71.4)        28 (65.1)    25 (67.6)    19 (57.6)    17 (45.9)
  Age (yr)                                                                                                                                        
   Mean±SD                                                                   57.0±11.30   56.2±9.38        54.8±12.60   55.0±12.23   50.5±11.25   57.6±13.54
   Range                                                                     33.5-72.5    31.7-74.4        26.2-73.6    30.0-76.0    32.0-74.7    34.0-87.0
  Country                                                                                                                                         
   China                                                                     14 (34.1)    17 (34.7)        15 (34.9)    0            0            0
   Hong Kong                                                                 0            3 (6.1)          2 (4.7)      0            0            0
   Republic of Korea                                                         20 (48.8)    20 (40.8)        13 (30.2)    0            0            0
   Taiwan, Province of China                                                 7 (17.1)     9 (18.4)         13 (30.2)                              
   Australia                                                                 0            0                0            3 (8.1)      0            0
   Brazil                                                                    0            0                0            15 (40.5)    5 (15.2)     8(21.6)
   India                                                                     0            0                0            15 (40.5)    27 (81.8)    25 (67.6)
   United Kingdom                                                            0            0                0            4 (10.8)     1 (3.0)      4 (10.8)
  *ECOG* performance status                                                                                                                       
   0                                                                         0            8 (16.3)         7 (16.3)     10 (27.0)    12 (36.4)    9 (24.3)
   1                                                                         38 (92.7)    40 (81.6)        34 (79.1)    23 (62.2)    16 (48.5)    26 (70.3)
   2                                                                         3 (7.3)      1 (2.0)          2 (4.7)      3 (8.1)      5 (15.2)     2 (5.4)
   3                                                                         0            0                0            1 (2.7)      0            0
  *EGFR* mutation status                                                                                                                          
   Yes                                                                       5 (12.2)     8 (16.3)         6 (14.0)     2 (5.4)      0            3 (8.1)
   No                                                                        5 (12.2)     4 (8.2)          3 (7.0)      5 (13.5)     2 (6.1)      0
   Unknown                                                                   31 (75.6)    37 (75.5)        34 (79.1)    30 (81.1)    31 (93.9)    34 (91.9)
  Pathological diagnosis                                                                                                                          
   Adenocarcinoma                                                            40 (97.6)    48 (98.0)        43 (100)     32 (86.5)    28 (84.8)    34 (91.9)
   Mixed cell lung carcinoma                                                 1 (2.4)      0                0            1 (2.7)      1 (3.0)      0
   Large cell lung carcinoma                                                 0            1 (2.0)          0            4 (10.8)     4 (12.1)     3 (8.1)
  Stage of disease^[a)](#tfn2-crt-2014-051){ref-type="table-fn"}^ at entry                                                                        
   IIIA                                                                      0            0                0            0            2 (6.1)      1 (2.7)
   IIIB                                                                      3 (7.3)      8 (16.3)         7 (16.3)     3 (8.1)      4 (12.1)     4 (10.8)
   IV                                                                        38 (92.7)    41 (83.7)        36 (83.7)    34 (91.9)    27 (81.8)    32 (86.5)

Values are presented as number (%) unless otherwise indicated. ITT, intent-to-treat; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.

Non-small cell lung cancer diagnosis stage IIIA, IIIB, or IV was per the definition by the American Joint Committee on Cancer staging criteria for lung cancer.

###### 

Cox regression analysis of PFS and OSa) adjusted by covariates^[a)](#tfn4-crt-2014-051){ref-type="table-fn"}^ (East Asian and non-East Asian ITT population)

  Variable                                                 East Asian         Non-East Asian                                                                            
  -------------------------------------------------------- ------------------ ---------------- ------------------ ------- ------------------ ------- ------------------ -------
  Treatment adjusted by covariates (overall)                                  0.003                               0.114                      0.210                      0.528
   Pemetrexed+erlotinib vs. erlotinib (reference level)    0.48 (0.29-0.79)   0.004            0.83 (0.44-1.56)   0.554   0.62 (0.37-1.05)   0.078   1.42 (0.72-2.80)   0.306
   Pemetrexed+erlotinib vs. pemetrexed (reference level)   0.40 (0.23-0.70)   0.001            0.53 (0.28-1.00)   0.051   0.75 (0.42-1.32)   0.320   1.00 (0.55-1.79)   0.993
   Pemetrexed vs. erlotinib (reference level)              1.20 (0.76-1.90)   0.430            1.56 (0.88-2.75)   0.124   0.83 (0.48-1.43)   0.505   1.43 (0.72-2.83)   0.309

PFS, progression-free survival; OS, overall survival; ITT, intent-to-treat; HR, hazard ratio; CI, confidence intervals.

PFS and OS were adjusted by three covariates: performance status (0-1 vs. 2), histologic subtype (adenocarcinoma vs. non-adenocarcinoma), and sex (female vs. male),

PFS was defined as the time from randomization to the first date of progressive disease (either objectively determined or clinical progression) or death from any cause; OS was defined as the time from randomization to the date of death from any cause; survival time was censored at the date of last contact for patients who were still alive or lost to follow-up,

The p-value was based on the Wald's test, with a two-sided significance level of 0.05.

###### 

Summary of ORR and DCR and regression analysis of ORR and DCR adjusted by covariates (East Asian and non-East Asian ITT evaluable population)

  Variable                                                                                     East Asian     Non-East Asian                                                                                                                                                                                                                                                                                        
  -------------------------------------------------------------------------------------------- -------------- ------------------- ---------------------------------------------------------- -------------- ------------------ ------------------------------------------------------- -------------- ------------------- ------------------------------------------------------- -------------- ------------------ -------------------------------------------------------
  Pemetrexed+erlotinib                                                                         21/41 (51.2)   (35.1-67.1)         \< 0.001^[b)](#tfn9-crt-2014-051){ref-type="table-fn"}^    29/41 (70.7)   (54.5-83.9)        0.107^[b)](#tfn9-crt-2014-051){ref-type="table-fn"}^    13/35 (37.1)   (21.5-55.1)         0.013^[b)](#tfn9-crt-2014-051){ref-type="table-fn"}^    20/35 (57.1)   (39.4-73.7)        0.804^[b)](#tfn9-crt-2014-051){ref-type="table-fn"}^
  Erlotinib                                                                                    15/49 (30.6)   (18.3-45.4)                                                                    25/49 (51.0)   (36.3-65.6)                                                                9/33 (27.3)    (13.3-45.5)                                                                 18/33 (54.5)   (36.4-71.9)        
  Pemetrexed                                                                                   5/43 (11.6)    (3.9-25.1)                                                                     22/43 (51.2)   (35.5-66.7)                                                                3/37 (8.1)     (1.7-21.9)                                                                  23/37 (62.2)   (44.8-77.5)        
  Treatment adjusted by covariates (overall)^[c)](#tfn10-crt-2014-051){ref-type="table-fn"}^                                      \< 0.001^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^                                     0.071^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^                                      0.037^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^                                     0.750^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^
   Pemetrexed+erlotinib vs. erlotinib (reference level)                                        \-             2.73 (1.12-6.68)    0.027^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^      \-             2.72 (1.08-6.80)   0.033^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             1.58 (0.56-4.52)    0.389^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             1.08 (0.41-2.89)   0.873^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^
   Pemetrexed+erlotinib vs. pemetrexed (reference level)                                       \-             9.45 (2.96-30.16)   \< 0.001^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             2.61 (1.01-6.75)   0.048^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             6.21 (1.54-25.00)   0.010^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             0.75 (0.29-2.00)   0.570^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^
   Pemetrexed vs. erlotinib (reference level)                                                  \-             0.29 (0.09-0.89)    0.031^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^      \-             1.04 (0.45-2.40)   0.923^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             0.26 (0.06-1.06)    0.060^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^   \-             1.44 (0.54-3.85)   0.473^[d)](#tfn11-crt-2014-051){ref-type="table-fn"}^

ORR, objective response rate; DCR, disease control rate; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat.

Confidence intervals were based on exact binomial probabilities,

Chi-square test was used for best ORR and DCR; Fisher exact test was used to compare response rates; all tests were at a two-sided significance level of 0.05,

Efficacy endpoints were analyzed on ITT randomized nonsquamous patients with measurable or evaluable lesions at baseline,

The p-value was based on the Wald\'s test, with a two-sided significance level of 0.05.

###### 

Summary of study drug-related TEAEs by maximum CTCAE grade ≥ 3 (East Asian and non-East Asian safety population^[a)](#tfn13-crt-2014-051){ref-type="table-fn"}^

  Toxicity                                  East Asian                                          Non-East Asian               
  ----------------------------------------- --------------------------------------------------- ---------------- --- --- --- ---
  Non-laboratory parameters                                                                                                  
   Grade 3/4 ≥ 5%                                                                                                            
    Mucositis/stomatitis                    4^[b)](#tfn14-crt-2014-051){ref-type="table-fn"}^   0                0   0   0   0
    Rash: acne/acneiform                    3                                                   4                0   1   1   0
    Diarrhea                                2                                                   0                0   5   0   0
    Fatigue (asthenia, lethargy, malaise)   2                                                   0                2   2   0   1
    Rash: desquamation                      1                                                   0                0   2   0   0
    Anorexia                                1                                                   0                0   0   0   2
   Grade 5                                                                                                                   
    Sudden death                            0                                                   0                0   0   0   1
    Viral hepatitis                         0                                                   0                0   0   0   1
  Laboratory parameters                                                                                                      
   Grade 3/4 ≥ 5%                                                                                                            
    Neutropenia                             11                                                  0                5   7   0   5
    Leukopenia                              3                                                   0                3   6   0   3
    Anemia                                  4                                                   0                3   4   0   4
    Lymphopenia                             3                                                   0                4   6   0   1
    Hyperglycemia                           2                                                   0                1   0   0   0
    Thrombocytopenia                        0                                                   0                1   2   0   1
    Hyponatremia                            0                                                   0                0   1   1   2
    Hypokalemia                             0                                                   0                0   1   0   2
   Grade 5                                                                                                                   
    Neutropenia                             0                                                   0                0   0   0   1
    Other blood/bone marrow                 0                                                   0                0   2   0   0

Values are presented as number (%).TEAEs, treatment-emergent adverse events; CTCAE, Common Terminology Criteria for Adverse Events; NOS, not otherwise specified.

Safety endpoints were analyzed on nonsquamous patients who received at least one dose of study therapy and according to the treatment they received in the first cycle,

Of these 4 patients, 1 patient (2.5%) experienced mucositis/stomatitis (clinical examination) and 3 patients (7.5%) experienced mucositis/stomatitis (functional/symptomatic).
